OverviewSuggest Edit

Our mission is to reduce the burden of treatment for patients with ocular diseases through the development of proprietary, injectable products enabling less frequent administration. Our lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. We are also developing new compounds to treat glaucoma and provide neuroprotection when injected twice per year into the subconjunctiva.

TypePrivate
Founded2011
HQRedwood City, US
Websitegraybug.com

Latest Updates

Employees (est.) (Oct 2020)33(+14%)
Cybersecurity ratingAMore

Key People/Management at GrayBug

Frédéric Guerard

Frédéric Guerard

Chief Executive Officer, Director
Emmett Cunningham

Emmett Cunningham

Director
Michael Keyoung

Michael Keyoung

Director
Gerald D. Cagle

Gerald D. Cagle

Director
Parisa Zamiri

Parisa Zamiri

Chief Medical Officer
Chau Q. Khuong

Chau Q. Khuong

Director
Show more

GrayBug Office Locations

GrayBug has offices in Redwood City and Baltimore
Redwood City, US (HQ)
275 Shoreline Dr #450
Baltimore, US
6411 Beckley St #200
Show all (2)

GrayBug Financials and Metrics

Summary Metrics

Founding Date

2011

GrayBug total Funding

$128.5 m

GrayBug latest funding size

$80 m

Time since last funding

a year ago

GrayBug investors

GrayBug's latest funding round in August 2019 was reported to be $80 m. In total, GrayBug has raised $128.5 m
Show all financial metrics

GrayBug Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Human Capital Metrics

Embed Graph
Show all human capital metrics

GrayBug Online and Social Media Presence

Embed Graph

GrayBug News and Updates

Graybug Vision's stock open up 19%, then pares some gains

Graybug Vision Inc.'s stock started its public life with a rally, as it opened 18.8% above its initial public offering price. The first trade was at $19.00 at 12:15 p.m. Eastern for 293,572 shares, above the upsized IPO price of $16 a share. At the IPO price, the California-based biopharmaceutical …

Graybug Appoints Three New Members to its Board of Directors

REDWOOD CITY, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vision-threatening diseases of the retina and optic nerve, today announced the appointment of thr…

Graybug Vision prices upsized IPO at midpoint of expected range, raises $90 million

Graybug Vision Inc. said early Friday that its upsized initial public offering priced at $16 a share, in the middle of the expected range of $15 to $17 a share. The California-based biopharmaceutical company focused on retina and optic never disease treatments sold 5.625 million shares in the IPO, …

Graybug Vision looks to raise up to $80 million as IPO terms set

Graybug Vision Inc. set terms of its initial public offering, in which the California-based biopharmaceutical company focused on retina and optic never disease treatments looks to raise $79.7 million. The company is offering 4.79 million shares in the IPO, which is expected to price between $15 and…

GrayBug Blogs

Graybug Vision Initiates Phase 2b (ALTISSIMO) Clinical Trial of GB-102 in Patients with Wet Age-Related Macular Degeneration

REDWOOD CITY, Calif., October 2, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal Read more…

Graybug Vision Initiates Clinical Trial in Macular Edema Secondary to Diabetic Macular Edema or Retinal Vein Occlusion

Redwood City, CA – September 18, 2019 –Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal Read more…

Graybug Vision Secures $80 million of Additional Funding to Advance its Potentially Transformative Retina and Glaucoma Clinical Programs

Redwood City, CA – August 20, 2019 – Graybug Vision, Inc., a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), Read more…
Show more

GrayBug Frequently Asked Questions

  • When was GrayBug founded?

    GrayBug was founded in 2011.

  • Who are GrayBug key executives?

    GrayBug's key executives are Frédéric Guerard, Emmett Cunningham and Michael Keyoung.

  • How many employees does GrayBug have?

    GrayBug has 33 employees.

  • Who are GrayBug competitors?

    Competitors of GrayBug include Cell Source, Harbour Antibodies and Rebiotix.

  • Where is GrayBug headquarters?

    GrayBug headquarters is located at 275 Shoreline Dr #450, Redwood City.

  • Where are GrayBug offices?

    GrayBug has offices in Redwood City and Baltimore.

  • How many offices does GrayBug have?

    GrayBug has 2 offices.